Kornimate/medical-research-clean huggingface dataset:
a study of disposable transnasal esophagoscope

Conditions: Gastroesophageal Reflux; Esophageal Varices; Esophageal Disease

Summary: this is a pilot study of a novel disposable transnasal esophagoscope for feasibility, safety and tolerance.

a disposable, transnasal esophagoscope, e.g. scantm was developed by intromedic co. ltd. (seoul, korea). this device was designed to allow patient to undergo endoscopy with minimum pain without sedation. this endoscopy system consists of thin probe with a cmos camera, controller and simple display system. this system is light enough to carry and does occupy much space, and thus, it can be used at patient bed sides in intensive care units, in emergency rooms, and even in doctor's offices.

Eligibility criteria:
inclusion criteria: 1. aged 20 years or older 2. endoscopy indicated for reflux symptoms (heartburn, epigastric soreness and/or regurgitation), dyspepsia (epigastric discomfort, bloating, early satiety), or non-cardiogenic chest pain, or known or suspected to have esophageal varices, infectious esophagitis, or other esophageal disease based on their medical history 3. a written informed consent form exclusion criteria: 1. history or symptoms of severe rhinitis and sinusitis 2. symptoms of acute respiratory inflammation at the time of examination 3. abnormal anatomy of the nasal cavity or nasopharynx due to nasal tumors or previous nasopharyngeal surgery 4. taking anticoagulants such as coumadin 5. patients for whom a egd could not be performed

Keywords: esophagoscope esophageal disease gastroesophageal reflux esophageal varices
ultrasound guided hematoma block in distal radius fractures

Conditions: Distal Radius Fractures; Fracture Dislocation; Dislocated Wrist; Dislocated Radius

Summary: this study will investigate the effectiveness of analgesia of ultrasound hematoma block compared to 'blind' hematoma block in patients with dislocated distal radius fracture.

distal radius fractures represent one of the most common injuries in the emergency department (ed). proper treatment especially for dislocated fractures can minimize the chance of residual injury. for closed reduction anesthesia is essential for safety, satisfaction and result. different methods of regional anesthesia can be used but hematoma block (hb) is the technique most often used in eds in the netherlands and recommended by dutch guidelines. in practice however a hb, does not always lead to adequate anesthesia, this might be because of poor infiltration into the fracture site. ultrasound could additionally provide real-time guidance of injection into the fracture site, maximizing the analgesic effect of hb. in this study the effectiveness of analgesia of ultrasound hb will be compared to 'blind' hb in patients with a dislocated distal radius fracture. patients with a confirmed dislocated fracture of the distal radius requiring closed reduction will be randomized to either ultrasound guided hematoma block or normal 'blind' hematoma block. nrs-scores will be given before, during and after hematoma block and during and after reduction of the fracture. these scores will be the primary endpoint of this study.

Eligibility criteria:
inclusion criteria: * age ≥ 16 years * confirmed fracture of the distal radius requiring closed reduction, defined as any off the following items(7): * \>10 degrees of dorsal angulation; * \>20 degrees of volar angulation; * \>2 mm step-off intra-articular; * \>3 mm radial shortening; * \>15 degrees radial inclination; * translation and non-intact radio-carpal alignment in the lateral view * significant translation in the posterior-anterior(pa)-view. exclusion criteria: * no informed consent can be given (cognitive impairment, severe dementia, no knowledge of dutch language e.a.) * neurovascular compromise or open fractures requiring (immediate) surgery or reduction. * first reduction already performed * multi-trauma patients requiring other urgent procedures/tests or with respiratory or hemodynamical compromise * pre-existent osteosynthesis material in situ in the affected arm * skin injury (with exception of minor abrasions), local infection or recent burns hindering or contra-indicating the use of ultrasound and ultrasound gel * allergy for local anesthetics

Keywords: distal radius fracture ultrasound hematoma block
glucocorticoid effects on cellular cytokine release

Conditions: Depressive Disorder; Fatigue Syndrome, Chronic; Fibromyalgia; Healthy; Inflammation

Summary: a variety of hormones and immune system processes are responsible for how the body responds to illness. this study concentrates on how the hormone cortisol effects the release of immune system factors called cytokines. cortisol is a hormone produced in the adrenal glands as a response to stimulation from the pituitary gland. abnormal levels of cortisol have been seen in several diseases such as depression and multiple sclerosis. cytokines are factors produced by certain white blood cells. they act by changing the cells that produce them (autocrine effect), altering other cells close to them (paracrine), and effecting cells throughout the body (endocrine effect). cytokines are important in controlling inflammation processes. in this study researchers would like to determine if changes in levels of hormones in the blood are associated with changes in cytokine levels. in addition, researchers would like to learn more about how cytokines respond to hormones in certain diseases.

many of the biochemical alterations observed in people suffering from major depression are changes in the concentrations and activity of components of the generalized stress response. these include the principal hypothalamic stimulus of pituitary-adrenal activation (corticotropin releasing hormone) and the locus ceruleus/norepinephrine system. the current study attempts to provide a clearer picture of the stability of changes during the acute illness, the treatment phase and the recovery process. we particularly wish to determine whether abnormalities in hpa axis perturbability in the well-state can be demonstrated, and if so how these are related to the acutely-ill state, since this information could provide a quantifiable phenotypic marker for depression.

Eligibility criteria:
healthy volunteers. depressed patients. fibromyalgia patients. chronic fatigue patients. subjects must not have been treated with steroids for more than two weeks during the previous year. subjects must not be on chronic medications. subjects must not have known medical problems or any condition which interferes with their immune system's ability to respond to infections (talk with your physician if you are not sure about a particular situation).

Keywords: il-1 il-6 immune response inflammation steroids chronic fatigue syndrome depression fibromyalgia normal volunteer
a study to assess the quality and strength of bone in women participants with osteoporosis taking oral ibandronate versus placebo

Conditions: Osteoporosis

Summary: the purpose of this randomized, double-blind, placebo-controlled study is to estimate the effect of oral ibandronate sodium (boniva) taken once monthly versus placebo on bone quality and strength at the proximal femur at one year.


Eligibility criteria:
inclusion criteria: * ambulatory, postmenopausal women between the age of 55 to 80 years diagnosed with osteoporosis * bmd t-score less than or equal to (\ =) -5.0 at all 3 sites exclusion criteria: * have been treated with other bisphosphonates or using chronic steroids within the past 6 months * have a history of major upper gastrointestinal (gi) diseases or have severe kidney dysfunction * have a spine fracture (identified on x-ray)

Keywords: osteoporosis bisphosphonates bone
laparotomy versus percutaneous puncture in patients with abdominal compartment syndrome during acute pancreatitis

Conditions: Mortality; Acute Pancreatitis

Summary: decompressive laparotomy with temporary abdominal closure, will decrease of overall mortality and major morbidity in patients with abdominal compartment syndrome during acute pancreatitis in comparison with percutaneous puncture with placement of abdominal catheter.

we anticipated that decompressive laparotomy with temporary abdominal closure, beside all potentially negative side effects that early open surgery carries in patients with acute pancreatitis, results in decrease of overall mortality and major morbidity. the decompress study is designed to compare effects of decompressive laparotomy with temporary abdominal closure and percutaneous puncture with placement of abdominal catheter in patients with abdominal compartment syndrome during acute pancreatitis.

Eligibility criteria:
inclusion criteria: * the study population consists of patients with acute pancreatitis complicated with development of abdominal compartment syndrome. exclusion criteria: * patients will not be enrolled to the study if any of the following criteria will be present: * age \ 80 years * recent surgical interventions * psychoses * pregnancy * previously history of chronic pancreatitis

Keywords: acute pancreatitis abdominal compartment syndrome decompressive laparotomy percutaneous abdominal puncture mortality of patients treated in both arms
thalidomide for the treatment of primary sclerosing cholangitis (psc)

Conditions: Primary Sclerosing Cholangitis

Summary: the purpose of this study is to determine the safety and benefit of thalidomide with primary sclerosing cholangitis (psc). this is a six month study.

at entry, patients will have a complete history and physical, blood tests, ultrasound, and will complete questionnaires. eligible patients will take thalidomide 400 mg once a day in the evening. patients will start a dose of 100 mg per day for two weeks, increasing by 100 mg per day every two weeks to a maximum dose of 400 mg per day for 6 months. patients will return at 6 months for an evaluation, blood tests and completion of questionnaires. blood tests will be performed by mailed-in kits at 3 months. patients will receive weekly phone calls for the first 2 months and bi-monthly thereafter.

Eligibility criteria:
inclusion criteria: * previous diagnosis of primary sclerosing cholangitis as defined by: serum alkaline phosphatase level greater than or equal to 1.5 times the upper limit of normal, negative serum antimitochondrial antibody test, cholangiography diagnostic of psc without other etiology for biliary obstruction, and liver histology consistent with or diagnostic of psc * patients must give written informed consent. * patients must be willing and able to comply with the most recent version of the fda-mandated system for thalidomide education and prescribing safety (s.t.e.p.s.®) program. exclusion criteria: * pregnant and/or lactating female * inability or unwillingness to practice contraceptive measures for the prevention of pregnancy * history of hypersensitivity reaction to thalidomide * inability to provide consent * findings suggestive of liver disease of other etiology such as primary biliary cirrhosis, chronic alcoholic liver disease, chronic hepatitis b and c infection, hemochromatosis, wilson's disease, alpha-1-antitrypsin deficiency, autoimmune hepatitis, and cryptogenic liver disease * anticipated need for liver transplantation in one year from decompensated chronic liver disease or recurrent variceal bleeding, spontaneous hepatic encephalopathy, or refractory ascites * treatment with tacrolimus, cyclosporine, sirolimus, ursodeoxycholic acid, corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, nicotine, silymarin, vitamin e or pirfenidone in the preceding three months * history of peripheral neuropathy * use of medications with significant drug-drug interactions with thalidomide * history of human immunodeficiency virus (hiv) positive status or acquired immunodeficiency syndrome (aids) * history of coexistent advanced malignancy * history of coexistent severe cardiovascular disease * history of coexistent severe renal disease * history of current excessive or recent (within 6 months) alcohol use * any condition that, in the opinion of the investigators, would interfere with the patient's ability to complete the study safely or successfully * history of thrombolytic events. combination use with corticosteroids increases risk of deep vein thrombosis.

Keywords: psc thalidomide
early versus late cholecystectomy after clearance of common bile duct stones

Conditions: Gallbladder and Bile Duct Calculi

Summary: approximately 10-15% of all patients with gallstones have coexisting common bile duct (cbd) stones. however cbd stones can also be formed in the absence of gallbladder stones. the current standard of treatment for calcular obstructive jaundice is endoscopic removal of the stones. endoscopic sphincterotomy (es) is widely accepted as the treatment of choice for patients with cbds. stone extraction is successful in up to 97% of patients the time interval between ercp and laparoscopic cholecystectomy (lc) is a matter of debate that may vary from days to months. some retrospective and other prospective studies have investigated this issue without sharp clue or definite conclusion this study planned to compare early lc (within admission) versus late lc (after 1 month) after ercp as regard technical difficulties and surgical outcomes.

the aim is comparing early versus delayed laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography in patients with gall bladder stones and calcular obstructive jaundice as regards operative difficulties, conversion rate, signs of inflammation, degree of adhesions, blood loss, postoperative morbidity, and hospital stay. moreover, bacterial examination of bile and culture sensitivity test for assessment of bacterial colonization and relate the degree of colonization to timing of laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography, to decide upon the optimal timing for the surgery. the study population will be divided into 2 groups; group (a) will be managed by early laparoscopic cholecystectomy (lc) within 3 days after ercp and group (b) will be managed by late lc one month after ercp.

Eligibility criteria:
inclusion criteria: * patients with cbd stone and treated by ercp exclusion criteria: * patient unfit for surgery, * pregnant patients, * patients with severe malnutrition, * patients with liver cirrhosis, * patients in whom endoscopic management of cbd stones failed * patients who experienced pancreatitis or perforation as a complication of the endoscopic management of cbd stones * patients who underwent previous upper abdominal surgeries * mentally retarded patients.

Keywords: time of cholecystectomy after ercp
calcium + vitamin d supplementation for low bone mass in adolescent idiopathic scoliosis (ais)

Conditions: Scoliosis

Summary: the purpose of this study is to determine whether calcium and vit d supplementation is effective for improving low bone mass in girls with adolescent idiopathic scoliosis (ais).

adolescent idiopathic scoliosis (ais) is a prevalent condition mainly affecting females with disease onset at early puberty. it can lead to serious health problems and is associated with low bone mass which can persist with growth. osteopenia is found to be an important prognostic factor for curve progression in ais. nutritional studies indicated ais subjects had low dietary calcium intake. evidences suggested that vit d insufficiency could be present in ais. calcium and vitamin d supplementation can therefore be a viable treatment option for low bone mass in ais subjects. the primary objective of this prospective randomized double-blinded placebo-controlled trial is to find out whether calcium and vitamin d supplementation can improve bone mineral density (bmd) in osteopenic ais subjects. the secondary objective of this study is to evaluate whether the supplementation is effective in controlling curve progression in ais.

Eligibility criteria:
inclusion criteria: * between the ages of 11-14 (tanner stage \< iv) * low bmd (z-score \< 0 from age-matched population mean) * cobb's angle greater or equal to 15° * presentation at the scoliosis clinic without prior treatment for low bone mass. exclusion criteria: * scoliosis with any known etiology such as congenital scoliosis, neuromuscular scoliosis, scoliosis of metabolic etiology, scoliosis with skeletal dysplasia, or * patient with known endocrine and connective tissue abnormalities, or * patient with eating disorders or gi malabsorption disorders or * prior treatment for low bone mass before being recruited into the study. * patient currently taking medication that affects bone metabolism eg corticosterone or estrogen.

Keywords: adolescent idiopathic scoliosis ais low bone mass osteopenia bone health bone density
a study to investigate the safety and possible clinical benefit of multistem(r) in patients with moderate to severe ulcerative colitis

Conditions: Colitis, Ulcerative

Summary: multistem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. factors expressed by multistem cells are believed to reduce inflammation and regulate immune system function, protect damaged or injured cells and tissue, promote formation of new blood vessels, and augment tissue repair and healing. multistem cell treatment resulted in significant efficacy in a mouse model of graft versus host disease with almost complete reversal of gastrointestinal pathology (similar to pathology that would be expected in ulcerative colitis). these data, together with safety data generated in 2 other clinical trials, suggest that multistem has the potential to be a new treatment option for patients with ulcerative colitis. this is the first study of multistem in this patient population and will cautiously explore the safety/toleration and potential benefit of this new treatment in patients with moderate to severe disease.


Eligibility criteria:
inclusion criteria: * subjects must have a documented diagnosis of ulcerative colitis at least 6 months prior to screening. * subjects must have active moderate-to-severe ulcerative colitis based on mayo score. * subjects must have modified baron endoscopic score of at least 2 determined within 7 days of first dosing. * subjects must have failed or be intolerant (as determined by the investigator) of at least one of the following treatments for uc: oral corticosteroids, azathioprine or 6-mercaptopurine (6-mp), or anti-tumor necrosis factor (tnf) therapy, eg, infliximab or adalimumab. * subjects must be on stable steroid doses. exclusion criteria: * subjects who have abnormal organ and marrow function. * subjects with a diagnosis of indeterminate colitis, or clinical findings suggestive of crohn's disease. * subjects who meet truelove-witts criteria for severe ulcerative colitis. * subjects receiving or who are expected to receive infliximab or other biologic treatment within 8 weeks of the day 1 study visit. * subjects receiving or who are expected to receive cyclosporine, mycophenolate, or tacrolimus within 4 weeks of the day 1 study visit.

Keywords: safety efficacy multistem(r) moderate to severe ulcerative colitis
efficacy study ii on remote ischemic conditioning for the prevention of stroke-associated pneumonia

Conditions: Stroke

Summary: verifying whether remote ischemic adaptation can reduce the occurrence of stroke related pneumonia in acute stroke patients within 24 hours of onset

verifying whether remote ischemic adaptation can reduce the occurrence and safety of stroke related pneumonia in acute stroke patients within 24 hours of onset

Eligibility criteria:
inclusion criteria: * age≥18 years old; * diagnosis of acute ischemic stroke; * remote ischemic conditioning or sham-remote ischemic conditioning can be treated within 24 hours after stroke onset * nihss score≥4; * subject or his or her legally authorized representative was able to provide informed consent. exclusion criteria: * during the screening period, body temperature ≥ 38 ℃; * evidence of lung infection, urinary tract infection or other infectious diseases during the screening period * expected lifespan less than 7 days * mechanical ventilation is expected to be required within 7 days; * anti-infective drug were used within 7 days prior to stroke; * uncontrolled hypertension with medication (defined as systolic blood pressure ≥200 mmhg and/or diastolic blood pressure ≥110 mmhg); * there are contraindications for remote ischemic conditioning (such as skin and soft tissue injury, fractures, peripheral arterial disease, etc. in the upper limbs); * history of autoimmune disease or malignancies; * use of immunosuppressive drug within the preceding 3 months; * pregnant or lactating, or pregnancy test positive; * current participation in another investigational trial; * other conditions are not suitable for this trial as evaluated by researchers.
collection and analysis of the clinical and biological characteristics of patients treated for giant cells arteitis (horton's disease)

Conditions: Giant Cell Arteritis; Horton Disease

Summary: giant cell arteritis (gca) or horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in france), potentially responsible for blindness. treatment: corticosteroid therapy, which is effective in the vast majority of cases. clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences: * cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity. * requires additional immunosuppressive treatment.


Eligibility criteria:
inclusion criteria: * patients aged 45 years or older * patients with giant cell arteritis according to acr criteria or revised criteria incorporating imaging parameters, * patients managed at the university hospital of carémeau in internal medicine from 01/01/2011 to 01/01/2020. exclusion criteria: none